{"id":"molgramostim-open-label","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2109134","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GM-CSF is a cytokine that promotes the differentiation and proliferation of hematopoietic progenitor cells into granulocytes and macrophages, thereby increasing their numbers and enhancing their antimicrobial and antitumor activity. By boosting innate immune cell populations and function, molgramostim aims to improve immune responses in conditions characterized by immune deficiency or dysfunction.","oneSentence":"Molgramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the production and activation of granulocytes and macrophages to enhance immune function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:05.474Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary alveolar proteinosis (PAP)"}]},"trialDetails":[{"nctId":"NCT06431776","phase":"PHASE3","title":"Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).","status":"RECRUITING","sponsor":"Savara Inc.","startDate":"2025-10-22","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":5},{"nctId":"NCT07342322","phase":"PHASE2","title":"A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-02-01","conditions":"Soft Tissue Sarcoma (STS)","enrollment":25},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":"Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm","enrollment":404},{"nctId":"NCT05677633","phase":"PHASE1","title":"Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2023-01-19","conditions":"Parkinson's Disease and Parkinsonism","enrollment":11},{"nctId":"NCT06100705","phase":"PHASE2","title":"Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-12-20","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":26},{"nctId":"NCT04229979","phase":"PHASE3","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-02-08","conditions":"Acute Myeloid Leukemia","enrollment":127},{"nctId":"NCT04544293","phase":"PHASE3","title":"Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Savara Inc.","startDate":"2021-05-19","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":164},{"nctId":"NCT03686683","phase":"PHASE3","title":"Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2018-10-18","conditions":"Adenocarcinoma of the Prostate","enrollment":532},{"nctId":"NCT03538314","phase":"PHASE1","title":"UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma","status":"COMPLETED","sponsor":"Ultimovacs ASA","startDate":"2018-07-09","conditions":"Malignant Melanoma","enrollment":30},{"nctId":"NCT03498716","phase":"PHASE3","title":"A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-02","conditions":"Triple Negative Breast Cancer","enrollment":2199},{"nctId":"NCT03421743","phase":"PHASE2","title":"Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection","status":"COMPLETED","sponsor":"Savara Inc.","startDate":"2018-03-01","conditions":"Mycobacterium Infections, Nontuberculous","enrollment":32},{"nctId":"NCT03482752","phase":"PHASE3","title":"Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis","status":"TERMINATED","sponsor":"Savara Inc.","startDate":"2018-04-16","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":60},{"nctId":"NCT05101356","phase":"PHASE1, PHASE2","title":"A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma","status":"RECRUITING","sponsor":"Tianhong Li","startDate":"2021-10-13","conditions":"Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma","enrollment":77},{"nctId":"NCT04314843","phase":"PHASE1","title":"Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma","status":"TERMINATED","sponsor":"Kite, A Gilead Company","startDate":"2020-05-26","conditions":"Relapsed/Refractory Large B-cell Lymphoma","enrollment":6},{"nctId":"NCT05344209","phase":"PHASE2","title":"Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Vestre Viken Hospital Trust","startDate":"2022-08-12","conditions":"Oncology, NSCLC Stage IV, NSCLC, Stage III","enrollment":138},{"nctId":"NCT02601365","phase":"PHASE1","title":"Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2019-03","conditions":"Acute Respiratory Distress Syndrome, Pneumonia, Respiratory Virus Infection","enrollment":""},{"nctId":"NCT02702180","phase":"PHASE2","title":"Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis","status":"COMPLETED","sponsor":"Savara Inc.","startDate":"2016-03-21","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":139},{"nctId":"NCT05790447","phase":"PHASE2","title":"Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-04-01","conditions":"Advanced Solid Tumor, Refractory Tumor","enrollment":60},{"nctId":"NCT04584112","phase":"PHASE1","title":"A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-09-28","conditions":"Triple-Negative Breast Cancer","enrollment":83},{"nctId":"NCT03597347","phase":"PHASE2","title":"Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection","status":"TERMINATED","sponsor":"Savara Inc.","startDate":"2019-06-20","conditions":"Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)","enrollment":14},{"nctId":"NCT04326920","phase":"PHASE4","title":"Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-03-24","conditions":"COVID-19","enrollment":87},{"nctId":"NCT04909515","phase":"PHASE2","title":"Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.","status":"WITHDRAWN","sponsor":"Y-mAbs Therapeutics","startDate":"2021-12-02","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT03458117","phase":"PHASE1","title":"T-VEC in Non-melanoma Skin Cancer","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2018-04-19","conditions":"Non-melanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma","enrollment":26},{"nctId":"NCT02009397","phase":"PHASE1, PHASE2","title":"A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2012-02","conditions":"Metastatic Melanoma","enrollment":27},{"nctId":"NCT00272493","phase":"PHASE2","title":"Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT02677155","phase":"PHASE2","title":"Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2016-01","conditions":"Follicular Lymphoma","enrollment":10},{"nctId":"NCT04197882","phase":"PHASE1","title":"Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-05-27","conditions":"Melanoma","enrollment":33},{"nctId":"NCT01363206","phase":"PHASE2","title":"Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma","status":"COMPLETED","sponsor":"Lynn E. Spitler, MD","startDate":"2011-05","conditions":"Malignant Melanoma, Metastatic","enrollment":29},{"nctId":"NCT02100930","phase":"NA","title":"Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-03","conditions":"Neuroblastoma","enrollment":69},{"nctId":"NCT04206358","phase":"PHASE1","title":"Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-05-13","conditions":"Melanoma","enrollment":30},{"nctId":"NCT04106180","phase":"PHASE2","title":"SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-09-30","conditions":"NSCLC Stage IV","enrollment":63},{"nctId":"NCT01183897","phase":"PHASE2","title":"3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08-12","conditions":"Neuroblastoma","enrollment":31},{"nctId":"NCT03306589","phase":"PHASE1","title":"Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-08-11","conditions":"Arthritis, Rheumatoid","enrollment":12},{"nctId":"NCT00088413","phase":"PHASE1, PHASE2","title":"PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-07-21","conditions":"Adenocarcinoma, Colorectal Cancer, Ovarian Cancer","enrollment":51},{"nctId":"NCT01487863","phase":"PHASE2","title":"Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2011-12","conditions":"Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":69},{"nctId":"NCT00621036","phase":"PHASE2","title":"Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-10-19","conditions":"Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder","enrollment":""},{"nctId":"NCT01981122","phase":"PHASE2","title":"A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2013-09","conditions":"Metastatic Prostate Cancer","enrollment":52},{"nctId":"NCT00938223","phase":"PHASE2","title":"Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma","status":"COMPLETED","sponsor":"Craig L Slingluff, Jr","startDate":"2000-08","conditions":"Melanoma","enrollment":51},{"nctId":"NCT00411086","phase":"PHASE2","title":"Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-11","conditions":"Lymphoma","enrollment":60},{"nctId":"NCT01338012","phase":"PHASE2","title":"Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Dendreon","startDate":"2011-12","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT01431391","phase":"PHASE2","title":"Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2011-09","conditions":"Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma","enrollment":68},{"nctId":"NCT00901342","phase":"PHASE2","title":"Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2009-10","conditions":"Prostate Cancer","enrollment":104},{"nctId":"NCT02520102","phase":"PHASE2","title":"Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia","status":"WITHDRAWN","sponsor":"Sanofi","startDate":"2017-02","conditions":"Acute Myeloid Leukemia NOS","enrollment":""},{"nctId":"NCT01704781","phase":"PHASE1, PHASE2","title":"Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)","status":"COMPLETED","sponsor":"Bionor Immuno AS","startDate":"2012-09","conditions":"HIV-1 Infection","enrollment":36},{"nctId":"NCT02240537","phase":"PHASE1","title":"Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer","status":"UNKNOWN","sponsor":"Benovus Bio, Inc.","startDate":"2015-01","conditions":"Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)","enrollment":4},{"nctId":"NCT00554372","phase":"PHASE2","title":"A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2008-08","conditions":"Carcinoma, Hepatocellular","enrollment":30},{"nctId":"NCT02243228","phase":"PHASE2","title":"Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2014-08","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":42},{"nctId":"NCT00308087","phase":"PHASE2","title":"Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-05","conditions":"Lymphoma, Follicular","enrollment":75},{"nctId":"NCT00329537","phase":"PHASE2","title":"Study of Sargramostim in Moderately to Severely Active Crohn's Disease","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-06","conditions":"Crohn's Disease","enrollment":11},{"nctId":"NCT00206700","phase":"PHASE2","title":"Open-label Trial of Leukine in Active Crohn's Disease","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2003-02","conditions":"Crohn Disease","enrollment":378},{"nctId":"NCT00893477","phase":"PHASE2","title":"GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"French Innovative Leukemia Organisation","startDate":"2009-03","conditions":"Lymphoma","enrollment":60},{"nctId":"NCT00896519","phase":"PHASE2","title":"GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"French Innovative Leukemia Organisation","startDate":"2009-03","conditions":"Lymphoma","enrollment":30},{"nctId":"NCT00785122","phase":"PHASE1, PHASE2","title":"IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)","status":"COMPLETED","sponsor":"Immatics Biotechnologies GmbH","startDate":"2008-06","conditions":"Colorectal Carcinoma","enrollment":92},{"nctId":"NCT00523159","phase":"PHASE2","title":"IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease","status":"COMPLETED","sponsor":"Immatics Biotechnologies GmbH","startDate":"2007-05","conditions":"Renal Cell Carcinoma","enrollment":68},{"nctId":"NCT00003269","phase":"PHASE2","title":"Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors","status":"COMPLETED","sponsor":"Scripps Health","startDate":"1998-02","conditions":"Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer","enrollment":20},{"nctId":"NCT00689143","phase":"PHASE1","title":"A Safety/Tolerability and Pharmakokinetic Study of Sargramostim Administrated in the Gingiva","status":"COMPLETED","sponsor":"Innoventus Project AB","startDate":"2008-08","conditions":"Periodontitis","enrollment":10},{"nctId":"NCT00510471","phase":"PHASE2","title":"Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma","status":"TERMINATED","sponsor":"Genitope Corporation","startDate":"2007-05","conditions":"Non-Hodgkin's Lymphoma","enrollment":""},{"nctId":"NCT00002008","phase":"PHASE1","title":"An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia","status":"COMPLETED","sponsor":"Sandoz","startDate":"","conditions":"HIV Infections, Cytopenias","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF)"],"phase":"phase_3","status":"active","brandName":"Molgramostim Open-label","genericName":"Molgramostim Open-label","companyName":"Savara Inc.","companyId":"savara-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Molgramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the production and activation of granulocytes and macrophages to enhance immune function. Used for Pulmonary alveolar proteinosis (PAP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}